Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its price objective lifted by equities research analysts at Piper Jaffray Companies from $20.00 to $26.00 in a research report issued on Thursday. Piper Jaffray Companies’ price target points to a potential upside of 97.27% from the company’s previous close.

HALO has been the topic of a number of other reports. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Friday, August 11th. BidaskClub upgraded shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Canaccord Genuity set a $16.00 price target on shares of Halozyme Therapeutics and gave the company a “buy” rating in a report on Wednesday, July 26th. ValuEngine upgraded shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Jefferies Group LLC reiterated an “underperform” rating and issued a $7.00 price target (up from $6.75) on shares of Halozyme Therapeutics in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $15.50.

Halozyme Therapeutics (NASDAQ HALO) traded up 18.36% during mid-day trading on Thursday, reaching $15.60. 10,530,905 shares of the company’s stock traded hands. The firm’s market cap is $2.09 billion. The firm’s 50-day moving average price is $12.63 and its 200 day moving average price is $13.19. Halozyme Therapeutics has a one year low of $8.18 and a one year high of $16.35.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The company had revenue of $33.80 million during the quarter, compared to the consensus estimate of $31.76 million. The business’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. On average, equities analysts forecast that Halozyme Therapeutics will post ($0.97) EPS for the current year.

WARNING: “Piper Jaffray Companies Boosts Halozyme Therapeutics, Inc. (HALO) Price Target to $26.00” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/piper-jaffray-companies-boosts-halozyme-therapeutics-inc-halo-price-target-to-26-00.html.

Several institutional investors have recently bought and sold shares of the company. IFP Advisors Inc increased its holdings in shares of Halozyme Therapeutics by 1.6% in the 2nd quarter. IFP Advisors Inc now owns 14,686 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 226 shares during the last quarter. ProShare Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 0.5% in the 2nd quarter. ProShare Advisors LLC now owns 82,187 shares of the biopharmaceutical company’s stock worth $1,054,000 after buying an additional 374 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its holdings in shares of Halozyme Therapeutics by 0.7% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 57,963 shares of the biopharmaceutical company’s stock worth $742,000 after buying an additional 396 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Halozyme Therapeutics by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 20,602 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 558 shares during the last quarter. Finally, Amalgamated Bank increased its holdings in shares of Halozyme Therapeutics by 5.3% in the 2nd quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 705 shares during the last quarter. Hedge funds and other institutional investors own 85.08% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.